Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant?
The most recent studies of the effect of polymorphisms of the angiotensin-converting enzyme gene on the pathogenesis of renal diseases and the response to treatment with angiotensin-converting enzyme inhibitors continue to produce conflicting results. Large prospective studies are required before angiotensin-converting enzyme genotyping will provide information that will assist in the assessment of prognosis and response to angiotensin-converting enzyme inhibitor treatment in individual patients. Until such studies are performed, all patients with chronic renal disease, regardless of angiotensin-converting enzyme genotype, should be considered candidates for angiotensin-converting enzyme inhibitor therapy.
Taal
M W
MW
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. mtaal@rics.bwh.harvard.edu
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000235:genetics; D005922:Glomerulonephritis, IGA / Q000235:genetics; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000235:genetics*; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000502:physiology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D007703:Peptidyl-Dipeptidase A